drugset / Trial / NCT00966368

Comparison of Two NN1250 Formulations in Healthy Volunteers

NCT00966368

Phase 1 Completed 27 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial was conducted in North America. The aim of this clinical trial was to investigate if two formulations of NN1250 (insulin degludec) have the same level of drug exposure to the body.

Timeline

Start
2009-08
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin degludec Protein / enzyme biologic 0.4 iu/kg Subcutaneous

Indications